Lee et al

Lee et al. inactivated vaccines are not quite definite. Therefore, we aimed to explore the safety, antibody responses, and B-cell immunity of T2DM patients who were vaccinated with inactivated coronavirus disease 2019 (COVID-19) vaccines. Methods Eighty-nine patients with Cot inhibitor-1 T2DM and 100 healthy controls (HCs) were enrolled, all of whom had received two doses of full-course inactivated vaccines. At 21C105?days after full-course vaccines: first, the safety of the vaccines was assessed by questionnaires; second, the titers of anti-receptor binding domain IgG (anti-RBD-IgG) and neutralizing antibodies (NAbs) were measured; third, we detected the frequency of RBD-specific memory B cells (RBD-specific MBCs) to explore the cellular immunity of T2DM patients. Results The overall incidence of adverse events was similar between T2DM patients and HCs, and no serious adverse events were recorded in either group. Compared with HCs, significantly lower titers of anti-RBD-IgG (values were reported, Cot inhibitor-1 with valuebody mass index, Hemoglobin A1c, Fasting Plasma Glucose Inactivated COVID-19 vaccines were safe in patients with T2DM The overall incidence of adverse events within 7?days of vaccination was 6.7% in the T2DM group and 6% in the HCs group. Within 30?days of vaccination, the overall incidence of adverse events in the T2DM group and HCs group was 5.6% and 8%, respectively. The differences between the two groups were not statistically significant (7?days: valuevalues (Tables ?(Tables33 and ?and44). Table 3 Multiple linear regression analysis for anti-RBD-IgG in T2DM patients valuebody mass index, Fasting Plasma Glucose, Hemoglobin A1c, CI confidential interval, standard Rabbit Polyclonal to MGST1 regression coefficient, DurbinCWaston: 1.926 valuebody mass index, Fasting Plasma Glucose, Hemoglobin A1c, confidential interval, standard regression coefficient, DurbinCWaston: 2.055 p?